Al Schroeder is the Co-Founder & Director of R&D at Eikonizo Therapeutics. AI has 15 years of experience in HDAC inhibitors for brain diseases and is the Co-inventor of first-in-class HDAC neuroimaging tool. Previously, Al was a Research Scientist at J.M.Hooker Lab, Martinos Center for Biomedical Imaging.
Al earned his Ph.D. in Biomedical Science, Neuroscience from the University of Massachusetts Medical School in 2008.
Eikonizo Therapeutics
Eikonizo is developing life-changing therapies by creating brain-penetrant small molecules and deploying in vivo target engagement techniques to accelerate the identification of therapeutics. Their first program is focused on a disease-modifying therapeutics for neurodegenerative diseases.